Marinus Pharmaceuticals, an early-stage biotech developing an add-on therapy for epilepsy, raised $45 million by offering 5.6 million shares at $8, well below the $12-$14 range. Marinus Pharmaceuticals will list on the NASDAQ under the symbol MRNS. Marinus Pharmaceuticals initially filed confidentially on April 4, 2014. Stifel and JMP Securities acted as joint bookrunners on the deal.
